[go: up one dir, main page]

DK2001492T3 - En metode til behandling af kræft og/eller cellulære proliferative tilstande og midler rettet mod hyaluronan anabolisme for samme formål - Google Patents

En metode til behandling af kræft og/eller cellulære proliferative tilstande og midler rettet mod hyaluronan anabolisme for samme formål

Info

Publication number
DK2001492T3
DK2001492T3 DK07718606.2T DK07718606T DK2001492T3 DK 2001492 T3 DK2001492 T3 DK 2001492T3 DK 07718606 T DK07718606 T DK 07718606T DK 2001492 T3 DK2001492 T3 DK 2001492T3
Authority
DK
Denmark
Prior art keywords
anabolism
treating cancer
same purpose
cellular proliferative
agents targeting
Prior art date
Application number
DK07718606.2T
Other languages
English (en)
Inventor
Tracey Brown
Gary Brownlee
Original Assignee
Alchemia Oncology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006901708A external-priority patent/AU2006901708A0/en
Application filed by Alchemia Oncology Ltd filed Critical Alchemia Oncology Ltd
Application granted granted Critical
Publication of DK2001492T3 publication Critical patent/DK2001492T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK07718606.2T 2006-03-31 2007-03-23 En metode til behandling af kræft og/eller cellulære proliferative tilstande og midler rettet mod hyaluronan anabolisme for samme formål DK2001492T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2006901708A AU2006901708A0 (en) 2006-03-31 A method of treatment and agents useful for same
PCT/AU2007/000359 WO2007112475A1 (en) 2006-03-31 2007-03-23 A method of treating cancer and/or cellular proliferative conditions and agents targeting hyaluronan anabolism useful for same

Publications (1)

Publication Number Publication Date
DK2001492T3 true DK2001492T3 (da) 2012-10-15

Family

ID=38562969

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07718606.2T DK2001492T3 (da) 2006-03-31 2007-03-23 En metode til behandling af kræft og/eller cellulære proliferative tilstande og midler rettet mod hyaluronan anabolisme for samme formål

Country Status (12)

Country Link
US (1) US20090068183A1 (da)
EP (1) EP2001492B1 (da)
JP (1) JP5334834B2 (da)
CN (1) CN101415431A (da)
AU (1) AU2007233549C1 (da)
CA (1) CA2643592A1 (da)
CY (1) CY1113424T1 (da)
DK (1) DK2001492T3 (da)
ES (1) ES2393210T3 (da)
PL (1) PL2001492T3 (da)
SI (1) SI2001492T1 (da)
WO (1) WO2007112475A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1678194E (pt) * 2003-10-10 2013-09-30 Alchemia Oncology Pty Ltd Modulação da síntese e degradação de hialuronano no tratamento de doença
US8460658B2 (en) 2003-10-10 2013-06-11 Alchemia Oncology Pty Limited Method of treating cancer and/or cellular proliferative conditions and agents targeting hyaluronan anabolism useful for same
EP2257299B1 (en) * 2008-03-07 2018-07-25 Research Development Foundation Modulation of srpx2-mediated angiogenesis
EP2336771A1 (en) * 2009-12-16 2011-06-22 Universität Duisburg-Essen HAS3v2 as tumor marker
CN109115764B (zh) * 2018-07-30 2021-06-15 深圳瑞达生物股份有限公司 环保型尿液羟苯衍生物检测试剂及其制备方法
CN112641947B (zh) * 2019-10-11 2023-02-03 沈阳福洋医药科技有限公司 一种抗肿瘤药物的筛选靶点、应用及筛选方法
US20240100124A1 (en) * 2021-01-27 2024-03-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Method of Treating Corneal Opacities and Scarring

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6423514B1 (en) * 1996-04-22 2002-07-23 Millennium Pharmaceuticals, Inc. Mammalian hyaluronan synthases, nucleic acids and uses thereof
US5994100A (en) * 1997-05-29 1999-11-30 Smithkline Beecham Corporation HAS2 splicing variant HOEFC11: a target in chronic renal failure, inflammatory diseases and myocardial ischemia
US6682904B1 (en) * 2002-08-15 2004-01-27 Deliatroph Pharmaceuticals, Inc. Specific inhibitors of hyaluronidase 2, and methods of identifying and using same
PT1678194E (pt) * 2003-10-10 2013-09-30 Alchemia Oncology Pty Ltd Modulação da síntese e degradação de hialuronano no tratamento de doença

Also Published As

Publication number Publication date
EP2001492B1 (en) 2012-09-12
AU2007233549B2 (en) 2012-01-12
JP5334834B2 (ja) 2013-11-06
EP2001492A1 (en) 2008-12-17
AU2007233549A1 (en) 2007-10-11
JP2009531333A (ja) 2009-09-03
SI2001492T1 (sl) 2012-12-31
PL2001492T3 (pl) 2013-01-31
CY1113424T1 (el) 2016-06-22
ES2393210T3 (es) 2012-12-19
CA2643592A1 (en) 2007-10-11
WO2007112475A1 (en) 2007-10-11
EP2001492A4 (en) 2010-02-17
US20090068183A1 (en) 2009-03-12
CN101415431A (zh) 2009-04-22
AU2007233549C1 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
BRPI0913129A2 (pt) método para tratamento de hiperuricemia empregando um inibidor de sglt2 e composição contendo o mesmo
DK2027360T3 (da) Fremgangsmåde og apparat til præparering af flersektionsborehuller
DK2127652T3 (da) Fremgangsmåde til behandling af cancer under anvendelse af anticancermiddel i kombination
BRPI0818426A2 (pt) produto de combinação, uso de um produto de combinação, e, método para tratar câncer
BRPI0908100A2 (pt) produto combinação, uso de um composto, e, método de tratar câncer
BRPI0807216A2 (pt) Fluido de tratamento, e, método para tratar uma formação subterrânea
FI20075961L (fi) Menetelmä ja laitteisto pienpanoslouhintaan
IL197217B (en) Novel anti-cd38 antibodies for the treatment of cancer
BRPI0819819A2 (pt) Preparações, método e kits ùteis para o tratamento de tosse
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
DK2001492T3 (da) En metode til behandling af kræft og/eller cellulære proliferative tilstande og midler rettet mod hyaluronan anabolisme for samme formål
FI20080217A0 (fi) Menetelmä ja laite lasin pinnoittamiseksi
DK2063881T3 (da) Sammensætning og fremgangsmåde til virksom og sikker administration af halopyruvat til behandlingen af cancer
BRPI0815726A2 (pt) terapia de combinação para câncer pancreático utilizando um peptídeo antigênico e agente quimioterápico
DK2187967T3 (da) Fremgangsmåde og sammensætninger til behandling af cancere
DK2037766T3 (da) Fremgangsmåde og system til forbedret anvendelse af akutiske bølger med høj intensitet
BRPI0818323A2 (pt) composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer.
DK2124547T6 (da) Fremgangsmåde til behandling af cancer
EP2267125A4 (en) INHIBITOR OF MOTILITY OF CANCER CELLS AND INFILTRATION OF CANCER CELLS
BRPI0810207A2 (pt) Métodos e composições para o tratamento de câncer
FI20075962L (fi) Menetelmä ja laitteisto pienpanoslouhintaan
DK2235021T3 (da) Epoxyguainderivater og behandling af cancer
FI20065691A0 (fi) Menetelmä ja laite taimien istuttamiseksi
FI20060373L (fi) Menetelmä ja laitteisto lasin pinnoittamiseksi